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Objective: The presence of reciprocal and Robertsonian chromosomal rearrangement is often related to
recurrent miscarriage. Using preimplantation genetic diagnosis, the abortion rate can be decreased. Cases
treated at our center were reviewed.
Materials and methods: A retrospective analysis for either Robertsonian or reciprocal translocations was
performed on all completed cycles of preimplantation genetic diagnosis at our center since the ﬁrst
reported case in 2004 until the end of 2010. Day 3 embryo biopsies were carried out, and the biopsied
cell was checked by ﬂuorescent in situ hybridization using relevant informative probes. Embryos with a
normal or balanced translocation karyotype were transferred on Day 4.
Results: Thirty-eight preimplantation genetic diagnosis cycles involving 17 couples were completed. A
total of 450 (82.6%) of the total oocytes were MII oocytes, and 158 (60.0%) of the two-pronuclei embryos
were biopsied. In 41.4% of the ﬂuorescent in situ hybridization analyses, the results were either normal or
balanced. Embryos were transferred back after 21 cycles. Three babies were born from Robertsonian
translocation carriers and another two from reciprocal translocation carriers. The miscarriage rate was
0%. Among the reciprocal translocation group, the live delivery rate was 8.3% per ovum pick-up cycle and
18.2% per embryo transfer cycle. Among the Robertsonian translocation group, the live delivery rate was
14.3% per ovum pick-up cycle and 20.0% per embryo transfer cycle.
Conclusion: There is a trend whereby the outcome for Robertsonian translocation group carriers is better
than that for reciprocal translocation group carriers. Aneuploidy screening may possibly be added in
order to improve the outcome, especially for individuals with an advanced maternal age. The emergence
of an array-based technology should help improve this type of analysis.
Copyright  2014, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Chromosome translocations refer to chromosome abnormalities
that are caused by the rearrangement of pieces of DNA between
nonhomologous chromosomes. Chromosome translocations are
mainly of two types: reciprocal and Robertsonian translocations.
Reciprocal translocations often involve an exchange of material
between nonhomologous chromosomes. They are found in about
one in 500 to one in 625 human newborns [1,2]. These trans-
locations are usually harmless and can be detected via prenatalnd Gynecology, Chang-Gung
oYuan 333, Taiwan.
e).
bstetrics & Gynecology. Publisheddiagnosis. A Robertsonian translocation involves two acrocentric
chromosomes that fuse near the centromere regionwith the loss of
the short arms. The resulting karyotype shows only 45 chromo-
somes in which two chromosomes are fused together. Neverthe-
less, there is no direct effect on the individual’s phenotype, because
the genes lost from the short arms of acrocentric chromosomes are
nonessential genes. Robertsonian translocations can involve all
combinations of acrocentric chromosomes. The most common
Robertsonian translocation in humans involves chromosomes 13
and 14, with an estimated incidence of 0.97/1000 newborns [3].
Recurrent miscarriage is often related to carrying either type of
translocation. In couples with two or more consecutive mis-
carriages, a rate of 2.3e4.5% for either Robertsonian or reciprocal
translocations has been noted [4,5]. Their subsequent pregnancy
outcome remains poor, with a miscarriage rate ranging from 36.4%by Elsevier Taiwan LLC. All rights reserved.
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genetic testing prior to their next attempt to conceive.
Preimplantation genetic diagnosis (PGD) is a type of genetic
testing in which a small number of cells are taken from embryos
in vitro for testing, and only embryos unaffected by the tested
condition are transferred into the woman’s uterus. The main goal is
to detect speciﬁc genetic diseases prior to implantation, in order to
avoid the possible consequence of selective pregnancy termination;
thus, this approach lowers the abortion rate.
Since our ﬁrst case reported in 2004 [6], 38 cycles with PGD
have been completed, involving either a Robertsonian or a recip-
rocal translocation. We review the results of these cycles of PGD in
order to provide a reference for future improvement.
Materials and methods
A retrospective analysis was performed of all completed cycles
of PGD at our center since the ﬁrst reported case in 2004, in which
either Robertsonian or reciprocal translocations had been detected.
Couples who requested PGD but did not undergo biopsy of the
embryo were not included in the review. Data on parental age, type
of translocation, reproductive history, and the sex of the carrier
were recorded.
Couples with either a Robertsonian or a reciprocal translocation
were identiﬁed when they came for PGD assistance. After full
counseling and informed consent, they underwent in vitro fertil-
ization (IVF) and embryo transfer (ET). Either the long protocol with
a gonadotropin-releasing hormone agonist or the gonadotropin-
releasing hormone antagonist protocol was used. Ovum pick-up
(OPU) using transvaginal ultrasound was carried out 34e36 hours
after the administration of human chorionic gonadotrophin (Pro-
fasi; Serono, Modungo, Italy), after two or more follicles had
reached a mean diameter of 18 mm.
Oocyte collection, insemination, and embryo culture
Oocytes were collected in a 4-(2-hydroxyethyl) piperazine-1-
ethanesulfonic acid-buffered commercial ﬂushing medium (Cook
Medical, Brisbane, Queensland, Australia). After serial washing,
each oocyte recovered was maintained at 37C in a separate drop of
fertilization medium (Cook Medical) equilibrated with 6% CO2 in
air. Intracytoplasmic sperm injection was carried out using motile
spermatozoa prepared by the swim-up procedure. The zygotes
were checked for the presence of pronuclei and polar bodies at 18e
21 hours after insemination or microinjection. Zygotes with two
pronuclei were cultured at 37C in a separate drop of cleavage
culture medium (Cook Medical) equilibrated with 6% CO2 in air
until Day 3.
Embryo biopsy and blastomere ﬁxation
Embryos that had reached seven or more cells (Grades I or II) on
Day 3 were selected for biopsy [7]. A 1.48 mm (infrared) diode laser
(Fertilase; MTM, Medical Technologies, Montreux SA, Switzerland)
connected to an inverted microscope (Diaphot 300; Nikon, Tokyo,
Japan) was used for zona drilling. The drilling consisted of four 10-
millisecond pulses. A 25e30 mm opening was made to allow the
entry of the embryo biopsy pipette (CookMedical). One blastomere
with a clear nucleus was aspirated from each embryo. A second
blastomere was aspirated only if the ﬁrst blastomere ﬁxation had
failed.
The aspirated blastomere was transferred and washed in
phosphate-buffered saline at room temperature. It was then placed
in a 10 mL drop of ﬁxative (0.1% Tween 20, 0.01 M HCl in distilled
water) on top of a poly-1-lysine-coated slide. The ﬁxative wasspread by continuous and gentle blowing until the cytoplasm dis-
solved. The ﬁnal position of the nucleus was marked using a dia-
mond pen. Dehydration was performed using ethanol of different
concentrations (70%, 90%, and 100%), and then the dry slide was
ready for the ﬂuorescent in situ hybridization (FISH) procedure.
Fluorescent in situ hybridization
The FISH method performed in our laboratory followed the
procedures described by Chen et al [8] and Harper and Delhanty
[9,10]. For the two translocation types, speciﬁc commercial probes
from Vysis (Abbott Laboratories, Abbott Park, Illinois, USA) were
chosen, which were able to identify the translocated and non-
translocated portions of the chromosomes (see Table 1). For each
PGD cycle, the probes were ﬁrst tested on the interphase nuclei of
male human leukocytes [9e11]. FISH signals were counted using
the criteria described by Hopman et al [12].
Embryo transfer and follow-up
As soon as the genotype of biopsied blastomeres were identi-
ﬁed, only the unaffected embryos or normal diploid embryos were
transferred, usually on Day 4. Pregnancies were conﬁrmed by uri-
nary tests or serum human chorionic gonadotropin levels at 2
weeks after ET. Clinical pregnancies were deﬁned as the presence of
one or more fetal hearts at 6e7 weeks of gestation. The implanta-
tion ratewas deﬁned as the number of fetal hearts per 100 embryos
transferred. The delivery rate was deﬁned as the percentage of
pregnancies with delivery per OPU and per ET procedure. Prenatal
diagnosis (2nd-trimester amniocentesis) was recommended to
conﬁrm the PGD results. Postnatal physical examinations were also
performed.
Statistical analysis
The fertilization rates and also the FISH results related to the
normal and balanced rates were compared between different
subgroups. Chi-square tests were used, and p < 0.05 was consid-
ered signiﬁcant.
Results
Among the couples requesting IVF and PGD, because of either a
reciprocal or a Robertsonian translocation, a total of 19 couples
completed OPU cycle. These consisted of 12 couples with reciprocal
translocations (8 male and 4 female carriers) and seven couples
with Robertsonian translocations (1 male and 6 female carriers). In
total, 17 couples went through at least one completed PGD cycle.
The remaining two couples (11%) did not have any embryo biopsy
results due to the lack of good embryos. As a consequence, 38 PGD
cycles from 17 couples were completed.
The karyotype and clinical features of the 19 couples are listed in
Table 1. Three out of nine male carriers suffered from a male factor.
One was a Robertsonian translocation and the other two were
reciprocal translocations. The most frequent Robertsonian trans-
location was der(13;14) (q10;q10). Among the reciprocal trans-
locations, chromosome 4 was most frequently involved and
chromosomes 1, 6, 10, 11, 13, and 15 were also common.
Segregation modes of the zygotes in female or male carriers
with Robertsonian translocation were as follows: normal 2:1
alternate, balanced 2:1 alternate, and the other six unbalanced
types, including 2 modes of 2:1 adjacent 1, 2 modes of 2:1 adjacent
2, and 2 modes of 3:0 nondisjunction. Therefore, only two of these
modes of embryos complements could be considered transferable.
The respective ﬂuorescent signal patterns were then recorded and
Table 1









45,XY,der(15,22)(q10;q10)/(1) CEP 15 Aqua, TelVysion 15q Orange,
TelVysion 22q Orange
2/4 Not pregnant Oligoathenoteratospermia
(8  106, 25%, 12.5%)
45,XX,der(13;14)(q10;q10)/(4) Vysis LSI (13q34) Green, TelVysion 14q Orange 6/23 Two preterm
infants, twins
Normal
45,XX,der(14;22)(q10;q10)/(2) Vysis LSI 22 BCR Green, TelVysion 14q Orange 5/23 Not pregnant Normal
45,XX,der(14;21)(q10;q10)/(2) Vysis LSI 21 Orange, Vysis LSI IGH/BCL2 Dual Color,
Dual Fusion Translocation Probe
2/4 Not pregnant Normal
45,XX,der(13,14)(q10;q10)/(1) Vysis LSI (13q34) Green, TelVysion 14q Orange 0/4 No transfer Normal
45,XX,der(13,14)(q10;q10)/(1) Vysis LSI (13q34) Green, TelVysion 14q Orange 2/6 One term infant Normal
45,XX,der(13;14)(q10;q10)/(1) Vysis LSI (13q34) Green, TelVysion 14q Orange 4/4 Not pregnant Normal
46,XY,t(13,22)(p13,q12)/(1) Vysis LSI (13q34) Green, TelVysion 22q Orange 7/14 Not pregnant Oligoathenoteratospermia
(3  106, 16.6%, 13.3%)
46,XY,t(9;10)(p24;q26)/(2) CEP 9 Aqua, TelVysion 9p Green, TelVysion 10q Orange 5/12 Not pregnant Normal
46,XY,t(4,11)(p14;q25)/(2) CEP 11 Aqua, TelVysion 4p Green, TelVysion 11q Orange 5/7 Not pregnant Normal
46,XY,t(6;11)(p23;q23)/(1) CEP 6 Aqua, TelVysion 6p Green, TelVysion 11q Orange 0/3 No transfer Normal
46,XY,t(7;13)(q34;q13)/(0) CEP 7 Aqua, TelVysion 7p Green, TelVysion 13q Orange 0/0 No biopsy Normal
46,XY,t(4,17)(p16;q11.2)/(0) CEP 4 Aqua, TelVysion 4p Green, CEP 17 Orange 0/0 No biopsy Normal
46,XY,t(2;15)(p23;q15)/(1) CEP 15 Aqua, TelVysion 15q Orange, TelVysion 2p Green 1/6 One chemical
pregnancy
Normal
46,XY,t(16,17)(q24;q12)/(2) CEP 16 Aqua, TelVysion 16q Orange,
TelVysion 17q Orange
8/10 One term infant Severe
athenoteratospermia
(79  106, 1.3%, 0%)
46,XX,t(4,18)(q31.1,q21.3)/(2) CEP 4 Aqua, TelVysion 4q Orange, TelVysion 18p Green 1/6 Not pregnant Normal
46,XX,t(1,15)(p22;q22)/(2) CEP 15 Aqua, TelVysion 15q Orange, TelVysion 1p Green 2/11 Not pregnant Normal
46,XX,t(6;10)(q15;p11.2)/(2) CEP 6 Aqua, TelVysion 6q Orange, TelVysion 10p Green 1/8 Not pregnant Normal
46,XX,t(1;5)(p10,q10) / (1) CEP 1 Orange, TelVysion 1p Green, TelVysion 5q Orange 4/13 One term infant Normal
PGD ¼ preimplantation genetic diagnosis.
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zygotes in female or male carriers of reciprocal translocations were
as follows: normal 2:2 alternate, balanced 2:2 alternate, and the
other 14 unbalanced types (including 2 modes of 2:2 adjacent 1, 2
modes of 2:2 adjacent 2, 2modes of 3:1 tertiary trisomy, 2modes of
3:1 tertiary monosomy, 2 modes of 3:1 interchange trisomy, 2
modes of 3:1 interchange monosomy, and 2 modes of 4:0 nondis-
junction). Only two of these modes of embryos complements could
be considered transferable. The respective ﬂuorescent signal pat-
terns were recorded and used to detect normal and balanced ones.
A total of 545 oocytes were retrieved at an average of 14.3 oo-
cytes per cycle (reciprocal: 12.8 and Robertsonian: 17.1). Of these,
450 (82.6%) oocytes of the MII oocytes and 263 (58.4%) of the MII
oocytes were normally fertilized (reciprocal: 58.3% and Rob-
ertsonian: 58.6%), whereas 158 (60.0%) of the two-pronuclei em-
bryos reached the criteria for Day 3 embryo biopsy. Altogether,
84.2% (133/158) of the biopsied embryos produced FISH results, and
41.4% (55/133) of the results were normal or balanced. Embryos
were transferred back after 21 cycles with an ET rate of 55.3% per
OPU cycle and 75% per embryo biopsy cycle.
The details of treatment of the 38 completed PGD cycles are
shown in Table 2. The data are grouped into reciprocal- and
Robertsonian-type translocations of either male or female carriers.
The normal fertilization rate (53.2%) among male carriers of a
reciprocal translocation is lower than that of female carriers
(66.7%), and this is statistically signiﬁcant (p¼ 0.04). A similar trend
can be noted for the Robertsonian translocation group (male car-
riers: 54.0% and female carriers: 60.7%). After the FISH testing of the
biopsied blastomeres, the normal or balanced rate (22.9%) of the
female carriers of reciprocal translocation was lower than that of
male carriers (57.8%), and this is statistically signiﬁcant (p ¼ 0.004).
A similar trend was noted for the Robertsonian translocation group
(female carriers: 38.8% and male carriers: 50.0%). The normal or
balanced rate (38.8%) among the female carriers of a Robertsonian
translocation is higher than that among the female carriers of the
reciprocal translocation (22.9%).Three babies including a pair of twins were born from carriers
with a Robertsonian translocation. Another two babies were born
from carriers with a reciprocal translocation. One chemical preg-
nancy occurred in one of the male reciprocal carrier group. The
miscarriage rate was 0%. For the reciprocal translocation group, the
live delivery ratewas 8.3% (2/24) per OPU cycle and 18.2% (2/11) per
ET cycle. For the Robertsonian translocation group, the live delivery
rate was 14.3% (2/14) per OPU cycle and 20.0% (2/10) per ET cycle.
Overall, the live delivery of this series was 10.5% (4/38) per OPU
cycle and 19.0% (4/21) per ET cycle.
Discussion
Although the ﬁrst clinical case of PGD was reported in the
literature in 1992 [13], PGD has only recently begun to be pro-
gressively accepted in Taiwan. Starting with our ﬁrst case reported
in 2004 [6], we have collected information on 38 cycles of recip-
rocal and Robertsonian translocation carrier couples, in which 28
cycles received embryo biopsies. The overall mean maternal age
was 34.9 years. Worldwide, chromosome rearrangements have
been an indication for PGD for a number of years [14]. According to
the latest published data collected for the calendar year 2007 by the
European Society for Human Reproduction and Embryology
(ESHRE) PGD consortium [15], there were 644 cycles to OPU for
reciprocal translocation or Robertsonian translocation carriers. In
the reciprocal translocation group seeking PGD help, the live de-
livery rate was 13.6% per OPU cycle and 23.9% per ET cycle. In the
Robertsonian translocation group, the live delivery rate was 22.1%
per OPU cycle and 32.1% per ET cycle. By comparison, our results
showed a live delivery rate of 8.3% per OPU cycle and 18.2% per ET
cycle for the reciprocal translocation group. Furthermore, the live
delivery rate for the Robertsonian translocation group was 14.3%
per OPU cycle and 20.0% per ET cycle. One possible reason for these
poorer results is that the mean female age of our patients is slightly
higher than that of the ESHRE PGD consortium (34.9 years vs. 34
years). Alternatively, the limited case numbermight also be a factor.
Table 2
IVF and PGD clinical data for the 19 couples with reciprocal and Robertsonian translocations.
Clinical data Reciprocal translocation Robertsonian translocation Total
Male carriers Female carriers Overall Male carriers Female carriers Overall
Mean female age 35.4 34.3 35.0 34 34.9 34.8 34.9
Cycles with ovum pick-up 15 9 24 2 12 14 38
Total oocytes retrieved 193 113 306 82 157 239 545
Oocytes/cycle with OPU 12.9 12.6 12.8 41 13.1 17.1 14.3
MII oocytes 156 96 252 63 135 198 450
Two-PN zygotes 83 (53.2%) * 64 (66.7%) * 147 (58.3%) 34 (54%) 82 (60.7%) 116 (58.6%) 263 (58.4%)
Cycles with embryo biopsy 9 7 16 1 11 12 28
Biopsied embryos 52 38 90 4 64 68 158
FISH results 45 35 80 4 49 53 133
Normal results 26/45 (57.8%) ** 8/35 (22.9%) ** 34/80 (42.5%) 2/4 (50.0%) 19/49 (38.8%) 21/53 (39.6%) 55 (41.4%)
Cycles with ET 7 4 11 1 9 10 21
Transferred embryo 17 8 25 2 18 20 45
Positive hCG 2 1 3 0 2 2 5
Ongoing pregnancies 1 1 2 0 2 2 4
Singletons 1 1 2 0 1 1 3
Twins 0 0 0 0 1 1 1
Live born deliveries 0 1 1 0 2 2 3
Live born children 0 1 1 0 2 3 4
*p ¼ 0.04 when normal fertilization rates were compared between male and female carriers.
**p ¼ 0.004 when results were compared between male and female carriers.
ET ¼ embryo transfer; FISH ¼ ﬂuorescent in situ hybridization; hCG ¼ human chorionic gonadotrophin; IVF ¼ in vitro fertilization; PGD ¼ preimplantation genetic diagnosis;
PN ¼ pronuclei.
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ertsonian group is better than that of the reciprocal group is similar
to that of the ESHRE report. Our results show that the normal
fertilization rates (53.2%; 54.0%) among the male carriers of recip-
rocal or Robertsonian translocation are lower than those (66.7%;
60.7%) of female carriers. After FISH tests on the biopsied blasto-
meres, the normal or balanced rates for female carriers (22.9%;
38.8%) are lower than those for the male carriers (57.8%; 50%). The
normal or balanced rate (38.8%) among the male carriers of Rob-
ertsonian translocations is higher than that among the female
carriers of reciprocal translocations (22.9%), which is similar to the
ﬁndings of ESHRE report. Interestingly, therefore, chromosome
rearrangements on the maternal side seem to have more effect on
the embryo than the paternal side rearrangements. A possible
explanation is that sperm may have to pass a checkpoint for un-
balanced chromosomal rearrangements or that a sperm with un-
balanced chromosomes has poor fertilizing ability.
Most cases of the female carrier group had a history of repeated
spontaneous abortions, whereas many of the male carrier group
had male infertility-related problems. These ﬁndings match con-
clusions outlined in previous literature [16]; it also implies that
chromosome status should be checked when male infertility is
encountered. As expected, most of the Robertsonian translocations
in this study were der(13;14) (q10;q10), which is the most common
Robertsonian translocation, as mentioned previously [16]. In terms
of reciprocal translocations, chromosome 4 was the most
frequently involved chromosome in our series, with chromosomes
1, 6, 10, 11, 13, and 15 also being involved frequently. The clinical
meaning of these ﬁndings remains to be elucidated.
Various opinions have been put forward, suggesting that there
are insufﬁcient data to support the hypothesis that PGD improves
the live birth rate in couples with recurrent miscarriage who carry a
structural chromosome abnormality. Nonetheless, one systemic
review showed a decreased miscarriage rate among couples who
seek PGD help [17]. The miscarriage rate among our limited cases
was 0%, which should be compared to the previously reported
miscarriage rates, which range from 36.4% to 72.4% [4,5]. On the
other hand, one recent meta-analysis of randomized control trials
by Mastenbroek et al [18] concluded that PGD-aneuploidy
screening (PGS) has no beneﬁcial effects on clinical pregnancy,miscarriage, and live birth rates among patient with an advanced
maternal age and repeated implantation failures. The nine RCTs in
that meta-analysis used FISH in all trials, and cleavage stage biopsy
was used in all but one trial. Technical drawbacks of FISH and the
possibility of chromosomal mosaicism are considered to underlie
the inefﬁcacy of PGS. Despite this, balanced translocation carriers
are still considered to be one of the main indications for using PGD,
and FISH remains the main methodology used.
There has been a concern that translocations, and perhaps other
chromosome rearrangements, disturb the meiotic disjunction of
chromosome pairs that are not involved in the translocation, which
then results in nondisjunction of these chromosomes (an inter-
chromosomal effect) and creates a predisposition toward trisomy
offspring [19]. This interchromosomal effect has been suspected to
play a role in Robertsonian translocations in particular, and such
aneuploidy exposes the couple to an additional risk of abnormal
pregnancy [20], although the effect may be slight and negligible
[21]. Therefore, PGS has been used as an additional approach in
order to improve the outcome, especially for couples with an
advanced maternal age. However, this was not performed in our
cases.
In the present series, cleavage-stage embryo biopsy was carried
out. There seems to be evidence supporting a high mosaicism rate
in cleavage-stage embryos, and this may be one reason why PGS
seems to provide no statistically signiﬁcant improvement in
outcome during clinical use [22,23]. Blastocyst biopsy is now under
investigation as a possible testing approach for use in PGS [24]. It
remains to be seen whether blastocyst biopsy is able to improve
PGD outcomes among chromosomal translocation carriers.
The emergence of array-based technology for clinical use allows
the analysis of all chromosomes [25]. Two types of arrays are being
developed for use as part of PGD: array comparative genomic hy-
bridization (aCGH) and single nucleotide polymorphism-based ar-
rays. The aCGH has been a part of PGD laboratory practice since
2006 [26] and has progressively been added to preimplantation
genetic screening [27,28]. DNAs from the test sample and from a
normal control are ampliﬁed using a whole genome ampliﬁcation
approach. The ampliﬁed DNAs are labeled separately with two
different ﬂuorochromes. After labeling with the different ﬂuoro-
chromes, the test DNA and the control DNA are mixed together in
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array platform that contains small pieces of chromosome (aCGH).
Recently, this approach has been applied to PGD for translocation
carriers [29,30]. The results so far have shown that this new
approach has the potential to overcome several inherent limita-
tions of FISH-based tests and is also able to provide improvements
in terms of test performance, automation, sensitivity, and reliability
[29]. Using aCGH, most patients with a chromosome rearrange-
ment seeking PGD help can be treated using a single protocol.
Additionally, it allows the detection of other chromosomal abnor-
malities unrelated to any rearrangement (such as aneuploidy),
which should assist the selection of viable embryos for transfer
[30]. Several centers in Taiwan have begun to use aCGH when
carrying out PGD for translocation carriers. An improvement in
outcome is expected in the future.
In conclusion, PGD should be considered as a treatment option
for translocation carriers, especially for couples who have had
repeated abortions, so that their miscarriage rate can be decreased.
Further possibilities to improve outcomes in the future include the
use of array-based technology and approaches other than Day 3
biopsy.Acknowledgments
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